We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
-0.18%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$383M
AUM Growth
+$150M
Cap. Flow
+$155M
Cap. Flow %
40.41%
Top 10 Hldgs %
48.06%
Holding
163
New
56
Increased
35
Reduced
10
Closed
61

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$20.5M
2
LLY icon
Eli Lilly
LLY
+$16.1M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$9.45M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$7.89M
5
ARGX icon
argenx
ARGX
+$7.32M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$9.05M
2
ABBV icon
AbbVie
ABBV
+$8.88M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$6.68M
4
BPMC
Blueprint Medicines
BPMC
+$5.6M
5
AZN icon
AstraZeneca
AZN
+$3.93M

Sector Composition

Rank Sector Weight
1 Healthcare 32.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EWTX icon
126
Edgewise Therapeutics
EWTX
$4.13B
– –
-1,359
Closed -$35.7K
GERN icon
127
Geron
GERN
$821M
– –
-200,000
Closed -$708K
GHRS icon
128
GH Research
GHRS
$1.93B
– –
-101,502
Closed -$711K
HALO icon
129
CALL
Halozyme
HALO
$9.76B
– –
-100,000
Closed -$4.78M
INSM icon
130
CALL
Insmed
INSM
$21.3B
– –
-50,000
Closed -$3.45M
INSM icon
131
Insmed
INSM
$21.3B
– –
-56,337
Closed -$3.89M
IOVA icon
132
CALL
Iovance Biotherapeutics
IOVA
$1.93B
– –
-100,000
Closed -$740K
JANX icon
133
PUT
Janux Therapeutics
JANX
$934M
– –
-17,500
Closed -$937K
KOD icon
134
CALL
Kodiak Sciences
KOD
$2.49B
– –
-7,300
Closed -$72.6K
KROS icon
135
Keros Therapeutics
KROS
$200M
– –
-63,547
Closed -$738K
LRMR icon
136
Larimar Therapeutics
LRMR
$413M
– –
-3,800
Closed -$14.7K
LRMR icon
137
PUT
Larimar Therapeutics
LRMR
$413M
– –
-16,900
Closed -$65.4K
LVTX
138
DELISTED
LAVA Therapeutics
LVTX
– –
-21,508
Closed -$20.5K
LXRX icon
139
CALL
Lexicon Pharmaceuticals
LXRX
$1.03B
– –
-800
Closed -$591
DFTX
140
Definium Therapeutics
DFTX
$5.55B
– –
-4,710
Closed -$32.8K
NKTR icon
141
Nektar Therapeutics
NKTR
$2.38B
– –
-46,595
Closed -$609K
NMRA icon
142
CALL
Neumora Therapeutics
NMRA
$304M
– –
-81,200
Closed -$861K
NUVL
143
DELISTED
Nuvalent
NUVL
– –
-14,701
Closed -$1.15M
ORIC icon
144
Oric Pharmaceuticals
ORIC
$1.1B
– –
-214,291
Closed -$1.73M
RCUS icon
145
Arcus Biosciences
RCUS
$3.47B
– –
-165,965
Closed -$2.47M
SABS icon
146
SAB Biotherapeutics
SABS
$290M
– –
-30,000
Closed -$114K
SMMT icon
147
PUT
Summit Therapeutics
SMMT
$10.4B
– –
-8,500
Closed -$152K
SPRY icon
148
CALL
ARS Pharmaceuticals
SPRY
$542M
– –
-3,200
Closed -$33.8K
SRRK icon
149
CALL
Scholar Rock
SRRK
$5.49B
– –
-43,000
Closed -$1.86M
TARS icon
150
Tarsus Pharmaceuticals
TARS
$2.68B
– –
-60,000
Closed -$3.32M
3 4 5
6
7

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return
FL
Fourthstone LLC St Louis, Missouri $590M AUM 29.58% 1-Year Est. Return
BA
Bellwether Advisors Lincoln, Nebraska $590M AUM 35.66% 1-Year Est. Return

Diadema Partners's Q1 2025 Portfolio in Review

As of Q1 2025, Diadema Partners held 163 positions worth $383M, up 64% from $233M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Diadema Partners deployed $155M of net new capital in Q1 2025, opening 56 new positions and adding to 35 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 29,828 shares worth $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 38% a quarter earlier.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $2.42M trimmed.

  • Diadema Partners's largest Q1 2025 buy was Regeneron Pharmaceuticals: 29,828 shares worth $18.9M.
  • Diadema Partners added most to Jazz Pharmaceuticals in Q1 2025, an estimated $9.45M increase.
  • Diadema Partners's biggest Q1 2025 reduction was Ascendis Pharma A/S, cutting an estimated $2.42M.
  • Diadema Partners fully exited Bristol-Myers Squibb in Q1 2025, selling an estimated $9.05M.
  • Diadema Partners's ten largest holdings make up 48% of its $383M portfolio in Q1 2025.
  • Diadema Partners opened 56 new positions and closed 61 in Q1 2025.
  • Diadema Partners's portfolio value rose 64% quarter-over-quarter to $383M.

Based on Diadema Partners's 13F filing for Q1 2025, filed 15 May 2025.